# Warby Parker Inc.: overview

WRBY · NYSE · CIK 1504776 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/wrby.md) · [Financials](/companies/wrby/financials.md) · [Filings](/companies/wrby/filings.md) · [Insiders](/companies/wrby/insiders.md)

Latest reported revenue: [$235.5m](/filings/0001504776-26-000019.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Aug 6, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0001504776-26-000019).

## Last eight quarters

| Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [192](/filings/0001504776-25-000033.md) | [191 d](/filings/0001504776-26-000006.md) | [224](/filings/0001504776-26-000011.md) | [214](/filings/0001504776-26-000019.md) | [222](/filings/0001504776-25-000033.md) | [212 d](/filings/0001504776-26-000006.md) | [242](/filings/0001504776-26-000011.md) | [236](/filings/0001504776-26-000019.md) |
| Gross margin | % | [54.5%](/filings/0001504776-25-000033.md) | [54.1% d](/filings/0001504776-26-000006.md) | [56.3%](/filings/0001504776-26-000011.md) | [53.0%](/filings/0001504776-26-000019.md) | [54.1%](/filings/0001504776-25-000033.md) | [52.4% d](/filings/0001504776-26-000006.md) | [54.0%](/filings/0001504776-26-000011.md) | [57.9%](/filings/0001504776-26-000019.md) |
| Operating margin | % | [(3.4%)](/filings/0001504776-25-000033.md) | [(4.9%) d](/filings/0001504776-26-000006.md) | [1.1%](/filings/0001504776-26-000011.md) | [(2.1%)](/filings/0001504776-26-000019.md) | [1.6%](/filings/0001504776-25-000033.md) | [(3.2%) d](/filings/0001504776-26-000006.md) | [0.7%](/filings/0001504776-26-000011.md) | [1.3%](/filings/0001504776-26-000019.md) |
| Net margin | % | [(2.1%)](/filings/0001504776-25-000033.md) | [(3.6%) d](/filings/0001504776-26-000006.md) | [1.6%](/filings/0001504776-26-000019.md) | [(0.8%)](/filings/0001504776-26-000019.md) | [2.6%](/filings/0001504776-25-000033.md) | [(2.8%) d](/filings/0001504776-26-000006.md) | [1.3%](/filings/0001504776-26-000019.md) | [2.0%](/filings/0001504776-26-000019.md) |
| Diluted EPS | $ per share | [(0.03)](/filings/0001504776-25-000033.md) | not reported | [0.03](/filings/0001504776-26-000011.md) | [(0.01)](/filings/0001504776-26-000019.md) | [0.05](/filings/0001504776-25-000033.md) | not reported | [0.03](/filings/0001504776-26-000011.md) | [0.04](/filings/0001504776-26-000019.md) |
| Free cash flow | $m | [13.1 d](/filings/0001504776-25-000033.md) | [2.2 d](/filings/0001504776-26-000006.md) | [13.2](/filings/0001504776-26-000011.md) | [23.9 d](/filings/0001504776-26-000019.md) | [(1.5) d](/filings/0001504776-25-000033.md) | [8.1 d](/filings/0001504776-26-000006.md) | [8.4](/filings/0001504776-26-000011.md) | [6.8 d](/filings/0001504776-26-000019.md) |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure.

## Last five fiscal years

| Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [541](/filings/0001504776-24-000006.md) | [598](/filings/0001504776-25-000010.md) | [670](/filings/0001504776-26-000006.md) | [771](/filings/0001504776-26-000006.md) | [872](/filings/0001504776-26-000006.md) |
| Gross margin | % | [58.8%](/filings/0001504776-24-000006.md) | [57.0%](/filings/0001504776-25-000010.md) | [54.5%](/filings/0001504776-26-000006.md) | [55.3%](/filings/0001504776-26-000006.md) | [54.0%](/filings/0001504776-26-000006.md) |
| Operating margin | % | [(26.6%)](/filings/0001504776-24-000006.md) | [(18.6%)](/filings/0001504776-25-000010.md) | [(10.7%)](/filings/0001504776-26-000006.md) | [(3.9%)](/filings/0001504776-26-000006.md) | [(0.6%)](/filings/0001504776-26-000006.md) |
| Net margin | % | [(26.7%)](/filings/0001504776-24-000006.md) | [(18.5%)](/filings/0001504776-25-000010.md) | [(9.4%)](/filings/0001504776-26-000006.md) | [(2.6%)](/filings/0001504776-26-000006.md) | [0.2%](/filings/0001504776-26-000006.md) |
| Diluted EPS | $ per share | [(2.21)](/filings/0001504776-24-000006.md) | [(0.96)](/filings/0001504776-25-000010.md) | [(0.54)](/filings/0001504776-26-000006.md) | [(0.17)](/filings/0001504776-26-000006.md) | [0.01](/filings/0001504776-26-000006.md) |
| Free cash flow | $m | [(80.5)](/filings/0001504776-24-000006.md) | [(49.8)](/filings/0001504776-25-000010.md) | [7.3](/filings/0001504776-26-000006.md) | [34.7](/filings/0001504776-26-000006.md) | [43.7](/filings/0001504776-26-000006.md) |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.

Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing.

## Insider purchases and sales

The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/wrby/insiders.md)

None in coverage.

## Funds that report holding it

From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md)

| Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before |
| --- | --- | ---: | ---: | --- | --- |
| [FMR LLC](/funds/315066.md) | 2026-06-30 | $472.6m | 15,577,440 |  | Added +51,068 |
| [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $464.5m | 15,309,616 |  | Added +8,050,553 |
| [JPMORGAN CHASE & CO](/funds/19617.md) | 2026-06-30 | $334.7m | 11,110,949 |  | Added +1,022,840 |
| [Durable Capital Partners LP](/funds/1798849.md) | 2026-06-30 | $194.1m | 6,396,513 |  | Unchanged |
| [VANGUARD PORTFOLIO MANAGEMENT LLC](/funds/2100121.md) | 2026-06-30 | $181.5m | 5,983,328 |  | Added +651,775 |
| [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $136.1m | 4,487,337 |  | Added +83,829 |
| [STATE STREET CORP](/funds/93751.md) | 2026-06-30 | $127.0m | 4,184,803 |  | Added +1,761,159 |
| [VAUGHAN NELSON INVESTMENT MANAGEMENT, L.P.](/funds/1021642.md) | 2026-06-30 | $94.3m | 3,107,226 |  | Added +78,919 |
| [GEODE CAPITAL MANAGEMENT, LLC](/funds/1214717.md) | 2026-06-30 | $78.0m | 2,571,338 |  | Added +197,002 |
| [FULLER & THALER ASSET MANAGEMENT, INC.](/funds/1082327.md) | 2026-06-30 | $72.7m | 2,397,130 |  | Added +84,193 |

## Recent filings

[All 506 filings](/companies/wrby/filings.md)

| Filed | Accepted | Form | What it is | Accession |
| --- | --- | --- | --- | --- |
| 2026-08-06 | 21:11 ET | [10-Q](/filings/0001504776-26-000019.md) | Quarterly report, period 2026-06-30 | 0001504776-26-000019 |
| 2026-08-06 | 10:46 ET | [8-K](/filings/0001504776-26-000015.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001504776-26-000015 |
| 2026-06-12 | 20:53 ET | [8-K](/filings/0001504776-26-000013.md) | 5.07 Shareholder vote results | 0001504776-26-000013 |
| 2026-05-07 | 20:44 ET | [10-Q](/filings/0001504776-26-000011.md) | Quarterly report, period 2026-03-31 | 0001504776-26-000011 |
| 2026-05-07 | 10:48 ET | [8-K](/filings/0001504776-26-000009.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001504776-26-000009 |
| 2026-04-28 | 20:46 ET | [DEF 14A](/filings/0001104659-26-050432.md) | Proxy statement, period 2026-06-08 | 0001104659-26-050432 |
| 2026-02-26 | 21:59 ET | [10-K](/filings/0001504776-26-000006.md) | Annual report, period 2025-12-31 | 0001504776-26-000006 |
| 2026-02-26 | 11:46 ET | [8-K](/filings/0001504776-26-000003.md) | 2.02 Results of operations; 8.01 Other events; 9.01 Financial statements and exhibits | 0001504776-26-000003 |
| 2026-02-09 | 21:19 ET | [8-K](/filings/0001104659-26-012081.md) | 5.02 Departure or appointment of officers or directors; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001104659-26-012081 |
| 2025-12-08 | 18:13 ET | [8-K](/filings/0001104659-25-119209.md) | 7.01 Regulation FD disclosure | 0001104659-25-119209 |

## Latest annual report

[Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001504776-26-000006.md), filed Feb 26, 2026.

## Forecast league

Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/5bafca01-10b4-45d8-9120-a66023c3282b)

## About the filer

- CIK: 1504776
- Tickers: WRBY
- Exchange: NYSE
- SIC code: 3851 Ophthalmic Goods
- State of incorporation: DE
- Filer category: Large accelerated filer

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:41 ET. No prices; not investment advice.